Morbidity and mortality of vulvar and vaginal cancers: Impact of 2-, 4-, and 9-valent HPV vaccines

Figures & data

Table 1. Vaccine information and potential impact by type.

	Cervarix®	Gardasil®	Gardasil-9®
HPV subtypes Covered	16, 18	6, 11, 16, 18	6, 11, 16, 18, 31, 33, 45, 52, 58
Disease reduction* (%) –vulvar	50.0	50.0	64.1
Disease reduction* (%) –vulvar in situ	82.4	82.4	92.7
Disease reduction* (%) –vaginal	56.7	56.7	80.0

Values for reduction are based on the most recent data regarding HPV subtypes implicated in vulvar and vaginal in situ and invasive disease. As such, potential impact would assume 100% efficacy and vaccine coverage. Saraiya M., Unger E., Thompson T., Lynch C., Hernandez B., Goodman M. (2015) US Assessment of HPV Types in Cancers: Implications for Current and 9-Valent HPV Vaccines. Journal of the National Cancer Institute. 107(6)